Comparing Colorectal Cancer Screening Test Performance and Prep Option

In this episode, ‘Comparing Colorectal Cancer Screening Test Performance and Prep Options,’ the panelists review the performance characteristics of available colorectal cancer screening modalities, including colonoscopy, FIT, multi-target stool DNA, RNA-based tests, and blood-based assays. The faculty compare sensitivity and specificity across tests, emphasizing that colonoscopy remains the most sensitive and uniquely therapeutic option. They highlight variability in FIT performance depending on assay type and cutoff thresholds, underscoring the importance of understanding which test is being used. Advances in next-generation stool DNA testing are discussed, with improved sensitivity and specificity compared to earlier versions. The conversation also addresses practical considerations such as bowel preparation options, patient adherence, and tailoring prep regimens to comorbidities to optimize both safety and diagnostic quality.

The next episode in this series, ‘Overcoming Barriers and Advancing Precision in Colorectal Cancer Screening,’ features expert faculty reviewing the barriers to colorectal cancer screening uptake, the evolving role of blood- and DNA-based testing, and the ongoing discussions around precision risk stratification and potentially lowering the screening age amid rising early-onset disease globally.

Videos

Clinicians share practical tips to boost colorectal screening, comparing colonoscopy and stool tests while addressing fears.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Video Series

Comparing Colorectal Cancer Screening Test Performance and Prep Options

Shared Decision-Making in Colorectal Cancer Screening 

In’ Shared Decision-Making in Colorectal Cancer Screening’, the panelists focus on practical strategies for engaging patients in colorectal cancer screening conversations and improving screening uptake. The faculty discuss how to present screening options—colonoscopy, stool-based testing, and other modalities—by outlining the risks, benefits, and trade-offs of each approach. Emphasis is placed on shared decision-making, addressing patient concerns about invasiveness, preparation, and potential complications while reinforcing the importance of early detection and cancer prevention. The speakers also highlight the role of stool DNA testing and FIT in average-risk patients and clarify expectations for follow-up colonoscopy after a positive result. Finally, the discussion underscores the importance of high-quality colonoscopy reporting and appropriate follow-through to ensure effective colorectal cancer prevention.

Our next episode, ’Colorectal Cancer Screening Modalities and Implementation Strategies,’ further explores the expanding range of colorectal cancer screening options, including FIT, stool DNA/RNA tests, and emerging blood-based assays. The panelists highlight the performance characteristics, intervals, and appropriate use for each screening option. The discussion emphasizes patient-centered selection, the necessity of colonoscopy for symptomatic or high-risk individuals, and the importance of tracking, follow-up, and updated surveillance intervals to ensure timely and effective screening.

Doctors share tactics to boost colorectal screening: compare colonoscopy vs stool tests, address fears, and prevent cancer before symptoms.

Shared Decision-Making in Colorectal Cancer Screening

Shara Bialo, MD, is the senior medical director of T1D immunology at Sanofi.

T1D Screening is Effective but Underused Among Patients With No Disease History, With Shara Bialo, MD

 screening can effectively predict the disease before the first symptoms appear; however, despite its efficacy, many patients are not offered screening and are only diagnosed after the first symptoms have appeared.

T1D is an inherited disease, and often a family history is the primary impetus for investigation and diagnosis. Relatives of patients with T1D have a roughly 15-fold greater risk of disease compared to those without a relative with T1D. However, roughly 90% of all patients who will present with new T1D do not have a positive family history.

“T1D gets a lot of attention for its metabolic consequences, but we’re starting to shift the focus a bit earlier to its true autoimmune roots, which is this underlying, silent disease evolution that doesn’t really call our attention until it’s clinically obvious,” Shara Bialo, MD, senior medical director of T1D immunology at Sanofi, told 

 in an exclusive interview. “However, it turns out that you can detect it months to years before clinical signs and symptoms emerge – and you do that through screening for T1D.”

T1D screening is typically conducted via a blood test, which is then investigated for autoantibodies created by the immune system to destroy insulin-producing cells. The presence of ≥2 diabetes-related antibodies warrants a diagnosis, although clinicians frequently corroborate this data by examining blood sugar levels.

Among the positive impacts of screening for T1D is the avoidance of diabetic ketoacidosis (DKA), a devastating and potentially life-threatening complication affecting longevity, morbidity, and quality of life. Previous trials have highlighted the efficacy of various methods of reducing the rate of DKA; among these, T1D screening and follow-up reduced the rate of DKA by 20%.

Low utilization of T1D screening is not due to limited access or high cost – most methods are free. Only a small number of patients are aware of the opportunity to predict T1D. Many clinicians have long been pushing for general population screening for T1D, which would help prevent major conditions such as DKA. However, logistical challenges, such as working with primary care physicians and optimizing cost-effectiveness, still prevent screening from being generalized to the full population.

Bialo discusses how patient awareness can be improved, suggesting that healthcare providers and clinicians emphasize the value of predicting and potentially forestalling the disease.

“Brief conversations can really make a meaningful difference for patients and their families, and it could start with simply knowing that screening exists,” Bialo said. “It’s okay for it to be a slow rollout, but over time, we should make our way to general population screening. We’ve been missing the vast majority of individuals who could be helped because we’ve kept our area of focus too narrow, but there’s definitely a chance to start somewhere.”

Editors’ Note: Bialo reports no relevant disclosures.

Sims EK, Besser REJ, Dayan C, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022;71(4):610-623. 

Centers for Disease Control and Prevention. Screening for type 1 diabetes. Centers for Disease Control and Prevention. February 23, 2026. Accessed March 12, 2026. 

https://www.cdc.gov/diabetes/diabetes-testing/screening-type-1-diabetes.html#cdc_generic_section_3-how-screening-works

Bialo discusses her perspective on the importance of T1D screening and its capacity to reduce the risk of disease progression and eventual complications later in life.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Sayantani Sindher, MD, is a clinical associate professor at the Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine.

Dupilumab Improves Desensitization Outcomes in OIT, With Sayantani Sindher, MD

2026 American Academy of Allergy, Asthma & Immunology (AAAAI)

 annual meeting in Philadelphia, found that adding dupilumab to omalizumab-facilitated 

improved desensitization outcomes and reduced gastrointestinal adverse events.

However, it did not significantly increase sustained unresponsiveness. This begs the question: How should clinicians counsel patients about expectations for desensitization versus sustained responsiveness?

“I'm always trying to figure out how to apply sustained unresponsiveness data to the patient sitting in front of me,” investigator Sayantani Sindher, MD, clinical associate professor of medicine at Stanford University, told 

during the meeting. “When you have a patient in front of you as an individual, it's really hard to [figure] out, ‘Okay, are you going to be someone who will achieve sustained unresponsiveness versus not? ‘ In my outpatient care, I don't take them off of [therapy for] a long period of time. If they do miss many days or months of treatment, I will bring them back in and do observed dosing to get them right back on track. Until we have biomarkers available that can predict sustained unresponsiveness, it is not something I'm able to readily apply in my outpatient clinical care practice.”

The randomized COMBINE trial enrolled 108 individuals with multiple food allergies (peanut plus 1 or 2 additional allergens) and investigated whether dupilumab could improve outcomes during omalizumab-assisted OIT. Participants first received omalizumab for 8 weeks, after which they received OIT with either dupilumab or placebo from weeks 8 through 32. All therapies were discontinued at week 32, and sustained unresponsiveness was evaluated at week 44 using double-blind, placebo-controlled food challenges.

Although the trial’s primary endpoint, sustained unresponsiveness to ≥1043 mg of peanut protein, was not statistically different between groups, results suggested potential benefits with dupilumab. Sustained unresponsiveness was achieved in 39% of patients receiving omalizumab plus OIT and 55% of those receiving dupilumab plus OIT (

Secondary findings showed improvements in desensitization and tolerability with the addition of dupilumab. By week 32, 92% of patients receiving dupilumab tolerated the highest tested allergen dose (4043 mg) during food challenge compared with 63% of those receiving OIT without dupilumab (adjusted 

 =.013). Investigators also reported fewer gastrointestinal symptoms and treatment withdrawals in the dupilumab group.

Despite encouraging signals, Sindher emphasized that translating combination biologic strategies into routine practice requires consideration of real-world factors such as insurance coverage and drug costs.

“In clinical trials, we have funding to obtain the drugs. In the outpatient world, it all goes through insurance, and access is a big deal,” Sindher said. “The cost of it is… something we have to think through before… we start using it.”

Future analyses of the COMBINE trial are exploring immune mechanisms underlying treatment responses, including assessments of B cells, T cells, and basophil activation. Sindher said these efforts may help identify patient subgroups most likely to benefit from combination biologic approaches and inform more personalized strategies for managing food allergy.

“What we need is a much better understanding of why it works,” Sindher said. “Who is the population it works best for, and also who is the population it doesn't work for? Once we have better predictive biomarkers or algorithms that help us phenotypically cluster these patients, it'll be really hard to know when to use these biologics…Many of our food allergic kids and adults also have many other atopic conditions [such as asthma, eczema, seasonal allergies, eosinophilic esophagitis] …Having different biologics approved for some of these indications that may also help for food allergy would really help us address multiple atopic conditions with just one drug.”

A relevant disclosure for Sindher includes Genentech USA.

Sindher S, Long A, Garcia-llorett M, et al. The addition of dupilumab enhances desensitization and reduces gastrointestinal symptoms in omalizumab-facilitated multi-allergen oral immunotherapy in the COMBINE trial. 

Journal of Allergy and Clinical Immunology

doi:https://doi.org/10.1016/j.jaci.2025.12.917

Sindher S. Dupilumab Reduces GI Symptoms During Multi-Allergen OIT, With Sayantani Sindher, MD. HCPLive. Accessed on March 12, 2026. Published on March 5, 2026. 

https://www.hcplive.com/view/dupilumab-reduces-gi-symptoms-multi-allergen-oit-sayantani-sindher-md

Data presented at AAAAI 2026 showed that adding dupilumab to omalizumab-facilitated oral immunotherapy improved desensitization and reduced gastrointestinal adverse events.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

 remains one of the most common yet underrecognized chronic conditions in the United States. Affecting an estimated 35–36 million individuals, the disease often progresses silently, leaving many patients unaware of their condition until significant kidney damage has occurred.

At a recent clinical forum examining challenges in CKD identification and management, Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, and clinicians across nephrology and cardiovascular medicine discussed the persistent gap between disease prevalence and clinical awareness.

The conversation focused on improving early detection, refining risk stratification, and integrating newer therapies into practice while navigating workforce constraints and evolving care models. Experts emphasized that recent therapeutic advances can only influence outcomes if CKD is identified earlier in its course.

A central theme of the discussion was the striking lack of patient awareness surrounding CKD. Despite affecting tens of millions of Americans, only a small fraction of patients know they have the disease. Because CKD often produces few symptoms in its early stages and screening practices remain inconsistent, many patients are first identified after kidney function has already declined significantly. Disparities in diagnosis and awareness also persist, particularly among younger individuals, women, and certain racial and ethnic populations.

Improving outcomes therefore begins with more consistent detection. Panelists highlighted the underuse of urine albumin-to-creatinine ratio (UACR) testing as a key contributor to missed diagnoses. While estimated glomerular filtration rate (eGFR) is commonly included in routine laboratory panels, albuminuria testing is obtained far less consistently. Yet albuminuria is a critical biomarker of kidney damage and a strong predictor of both CKD progression and cardiovascular risk.

Several experts described efforts to reframe albuminuria testing as an early warning signal for kidney disease. When paired with eGFR, UACR can help clinicians identify patients earlier and better assess their risk of progression. Expanding the routine use of these tests was widely viewed as one of the most practical steps toward improving early CKD detection.

The forum also examined evolving referral patterns to nephrology. Some clinicians reported increased referrals from primary care, particularly from advanced practice providers, though referrals remain inconsistent. In many cases, patients are referred late in the disease course—sometimes only when kidney failure is imminent or dialysis planning is required—limiting opportunities to slow progression.

At the same time, experts acknowledged a practical reality: the nephrology workforce cannot manage every patient with early-stage CKD. With diabetes, hypertension, and cardiovascular disease continuing to rise, the population at risk for kidney disease is expanding rapidly. As a result, more effective triage and risk stratification are needed to ensure nephrology resources are directed toward patients most likely to benefit from specialist care.

Rather than relying solely on eGFR thresholds, panelists emphasized a more nuanced approach to referral decisions. Factors such as albuminuria levels, rate of kidney function decline, structural abnormalities, and underlying disease etiology can help determine which patients require specialist involvement. Many individuals with stable kidney function and minimal albuminuria may be appropriately managed in primary care with careful monitoring and risk factor control.

Strengthening collaboration between primary care clinicians and nephrologists will be essential for making these models work. Education around CKD biomarkers and referral criteria can help clinicians better identify which patients require specialist care and which can be safely managed in the community.

Recent advances in CKD therapeutics have added urgency to improving early detection. Over the past several years, therapies such as sodium-glucose cotransporter 2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists have demonstrated the ability to slow CKD progression while reducing cardiovascular risk. Dapagliflozin and empagliflozin, as assessed in the DAPA-CKD and EMPA-KIDNEY trials, respectively, represent a major shift in CKD care, moving the field closer to disease modification rather than simply managing complications.

However, the benefits of these therapies depend heavily on early identification. If CKD remains undetected until advanced stages, opportunities to meaningfully alter disease trajectory may already be lost.

For clinicians, the message from the forum was clear: the tools to change CKD outcomes now exist, but realizing their full potential will require earlier recognition and a healthcare system capable of moving kidney care further upstream.

US Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. May 15, 2024. Accessed March 12, 2026. 

https://www.cdc.gov/kidney-disease/php/data-research/index.html

American Kidney Fund. Risk factors for kidney disease. Accessed March 12, 2026. 

https://www.kidneyfund.org/all-about-kidneys/risk-factors

Campbell P. Dapagliflozin (Farxiga) Receives Historic FDA Approval for Chronic Kidney Disease. HCPLive. April 30, 2021. Accessed March 12, 2026. 

https://www.hcplive.com/view/dapagliflozin-farxiga-receives-historic-fda-approval-for-chronic-kidney-disease

Campbell P. Empagliflozin (Jardiance) Receives CKD Approval from US FDA. HCPLive. September 22, 2023. Accessed March 12, 2026. 

https://www.hcplive.com/view/empagliflozin-jardiance-receives-ckd-approval-from-us-fda

Articles

Chronic kidney disease affects 35–36 million Americans yet frequently goes unrecognized until late, reflecting limited patient awareness and inconsistent screening. Underuse of urine albumin-to-creatinine ratio testing, despite routine eGFR reporting, drives missed early diagnosis and inadequate risk stratification. Referral to nephrology often occurs near kidney failure, while workforce limitations necessitate better triage models that incorporate albuminuria, trajectory of decline, etiology, and structural findings. Therapeutic advances—particularly SGLT2 inhibitors and nonsteroidal MRAs—heighten urgency to shift kidney care upstream.

Experts discuss gaps in CKD detection, the role of albuminuria testing, and the need for earlier, risk-based care to improve outcomes.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Improving Early Detection of CKD in an Evolving Cardio-Kidney-Metabolic Era

Lala discusses the ethical, medical, and practical concerns surrounding xenotransplantation of pig hearts – and how they should be addressed in clinical research.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

ISHLT Provides Updates in Xenografting in Patients with Cardiac Diseases, With Anu Lala, MD

This segment of Bhatia's interview highlights imsidolimab's reported durability of response for those with generalized pustular psoriasis (GPP).

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

Division of Nephrology in the Department of Medicine at Columbia University Irving Medical Center and the Columbia University Renal Epidemiology (CURE) Group in New York

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants. 

Is Expedited Kidney Donation More Effective Than In-Sequence?

Vice Chief of Education, Fellowship Program Director

Division of Gastroenterology and Hepatology at UNC Health Care

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Wood discussed factors that go into shared decision making for multi-food allergy.

Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

Daniel DiGiacomo, MD, a clinical immunologist at K. Hovnanian Children's Hospital at Hackensack Meridian Jersey Shore University Medical Center. 

At AAAAI 2026, DiGiacomo discussed how artificial intelligence, genetic testing, and biomarkers could improve diagnosis and precision care.


AI, Genetic Testing May Advance Precision Care in Immunology, With Daniel DiGiacomo, MD

Caleb Alexander, MD, MS, is a professor of epidemiology and medicine at Johns Hopkins University School of Medicine and co-founder and principal of Stage Analytics.

Alexander discusses his recent study comparing 61 trials of 4 main GLP-1 RAs, highlighting their increased efficacy for weight loss in female patients.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

GLP-1 RA Effects are Largely Homogeneous but Stronger in Women than Men, With Caleb Alexander, MD, MS

In this episode, experts discuss solitary confinement, aging in prison, and gaps in care for incarcerated populations.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Medical Ethics Unpacked

Medical Ethics Unpacked is a regular multimedia series hosted by Dominic Sisti, PhD, and Steve Levine, MD, spotlighting a spectrum of topics within the field of medical ethics. Throughout the year, hosts will sit down for an in-depth discussion on a specific ethical dilemma within modern healthcare, with some episodes also featuring a special guest. 

Check back throughout the year for discussions on a variety of topics, including data privacy in health apps, euthanasia and medical assistance in dying, reproductive rights and technologies, and more!

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Medical Ethics Unpacked: Ethical Challenges of Carceral Healthcare

Explore emerging IBD treatments—TL1A blockers, microRNA, stem cells—and new small-bowel imaging, plus team-based care improving access.

UChicago Advances IBD Trials With Focus on Microbiome and Access

Senior Allergy Dietitian at the Royal Children’s Hospital, Clinician-Scientist Fellow at MCRI & Honorary Senior Research Fellow at Melbourne University,

McWilliam discussed findings from the TreEat study at AAAAI 2026.

Latest News

Comparing Colorectal Cancer Screening Test Performance and Prep Options

Shared Decision-Making in Colorectal Cancer Screening

T1D Screening is Effective but Underused Among Patients With No Disease History, With Shara Bialo, MD

Dupilumab Improves Desensitization Outcomes in OIT, With Sayantani Sindher, MD

Improving Early Detection of CKD in an Evolving Cardio-Kidney-Metabolic Era